drugset / Trial / NCT03330990
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
NaSingle-groupOpen-labelOther
Summary
This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
Timeline
- Start
- 2017-11-14
- Primary completion
- 2018-07-11
- Completion
- 2018-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entrectinib | Small molecule | 600 mg | Oral |
| Subject | Midazolam | Small molecule | 2 mg | Oral |